Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment
Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. ("Hanmi"). The loan is convertible as prepayment of milestone obligations under the Future Collaboration Agreement (as defined hereinafter) or repayable after the expected completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients. Aptose will use the proceeds from such loan for the development of tuspetinib.
Aptose Biosciences Inc.（「Aptose」 或 「公司」）（納斯達克股票代碼：APTO，多倫多證券交易所股票代碼：APS）是一家臨床階段的精準腫瘤學公司，開發用於治療急性髓系白血病（AML）患者的高度差異化口服激酶抑制劑塔斯佩替尼今天宣佈，它通過與韓美製藥公司的融資協議獲得了1000萬美元的貸款。有限公司（「Hanmi」）。該貸款可兌換爲未來合作協議（定義見下文）下的里程碑義務的預付款，也可以在針對新診斷的急性髓細胞白血病患者進行的一項使用託斯培替尼的三聯藥物試驗預計完成後償還。Aptose將把此類貸款的收益用於開發塔斯佩替尼。
Beyond the $10 million Facility Agreement, Aptose and Hanmi have agreed to negotiate a new tuspetinib co-development collaboration agreement (the "Future Collaboration Agreement'), intended to provide additional funding to accelerate clinical development of tuspetinib. Aptose licensed tuspetinib from Hanmi Pharmaceutical in November 2021.
除了1000萬美元的融資協議外，Aptose和Hanmi還同意就一項新的tuspetinib聯合開發合作協議（「未來合作協議」）進行談判，旨在提供額外資金以加速tuspetinib的臨床開發。Aptose 於 2021 年 11 月從韓美製藥獲得了 tuspetinib 的許可。
